A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer

By C. Braicu, Mihail Buse, C. Busuioc, Rareș Drula, D. Gulei, L. Raduly, A. Rusu, A. Irimie, A. Atanasov, O. Slabý and 2 more. Cancers, 2019

811 citations recorded by the source corpus.

The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses. Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes. Numerous studies focused on both the homeostatic and the pathologic conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclinical and clinical research. MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to experimental MAPK inhibition. The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways. Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components. Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.

Subfields: Computational Theory and Mathematics, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/ff23f1e88b7ca621b73323b68e9b7ab12a96998d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pathology and Forensic Medicine

Citations in the corpus

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “48 For example, a CRISPR/cas9 gene deletion study in lung cancer cells revealed that the deletion of KEAP1, in the presence of speci ﬁ c RAS/RAF/MAPK pathway inhibitors, alters cell metabolism and enables cells to proliferate without MAPK signaling.”
ERK/MAPK signalling pathway and tumorigenesis (2020, background): “The activation of the ERK/MAPK signalling pathway can increase tumour invasion and metastasis by upregulating MMP expression, while inhibition of this signalling pathway can reduce tumour invasion and metastasis (110-111).”